Caris Life Sciences (CAI) Stock: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$28.35
-2.28 (-7.44%)
▼
5d:
-12.15%
30d:
+14.41%
90d:
+54.92%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CAI is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CAI is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $28.35, which is considered fair relative to its 30-day fair value range of $25.00 to $30.69. From a valuation perspective, the stock is trading at a premium (Forward PE: 75.5) compared to its historical average (53.8). At these levels, the market is pricing in 12.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAI is in a strong uptrend. The price is currently testing key support at $28.29. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: CAI scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is in a strong uptrend. The price is currently testing key support at $28.29. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: CAI scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$25.00 -
$30.69
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
39.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- NEUTRAL: Near Wall St target ($28.15)
- NEUTRAL: Trading at premium valuation - market expects 12.0% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.00 -
$30.69
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$28.29
Resistance Level
$32.89
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
75.48
Wall Street Target
$28.15
(-0.7%)
Revenue Growth (YoY)
45.4%
Profit Margin
10.6%
Valuation Premium vs History
+12.0% premium
PE vs Historical
75.5 vs 53.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.0%
(market-implied from PE analysis)
1-Year Target
$31.75
(+12%)
2-Year Target
$35.56
(+25%)
3-Year Target
$39.83
(+41%)
3-Yr Target (if PE normalizes)
(PE: 75→54)
PE COMPRESSION
$28.39
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 75.5, Growth: 171.2%)
$95.68
(+238%)
Base:
(SPY PE: 20.4, Growth: 171.2%)
$25.86
(-9%)
Bear:
(PE: 17.3, Growth: 171.2%)
$21.98
(-23%)
📈
Valuation based on Current Earnings
Trailing PE: 3.20 | Current EPS (TTM): $9.58
Bull Case
$16.85
(-41%)
Analyst growth -50.0%, PE expands to 3.5
Base Case
$15.32
(-46%)
Market implied -50.0%, PE stable at 3.2
Bear Case
$20.83
(-27%)
Severe decline -20.0%, PE contracts to 2.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 2:26 AM ET
Data refreshes hourly during market hours. Next update: 3:26 AM
Data refreshes hourly during market hours. Next update: 3:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 50 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |